Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

Lyon, Rhône 69373

0 studies enrolling now · 3 studies all time

What they study most

Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Metastatic or Unresectable Cutaneous Melanoma, TGCT

Studies at this site

• Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) — Running, not enrolling
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed